HCA Healthcare, Inc.
HCA · Healthcare
$413.58
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River Laboratories (CRL) shares have gained 10.5% since its Q2 2026 earnings report, outperforming the S&P 500. The company beat earnings estimates with non-GAAP EPS of $3.02 and raised its 2026 guidance, though revenues declined 2.7% year-over-year. However, estimates have been trending downward since the earnings release, and the stock carries weak VGM scores despite maintaining a Zacks Rank #2 (Buy) rating.
Can Operational Resiliency Protect HCA's Long-Term Profitability?
HCA Healthcare is leveraging its multi-year resiliency program focused on digital transformation and shared services to control unit costs and maintain profitability despite facing a $1.0-$1.2 billion headwind from health insurance exchange disenrollment in 2026. The company achieved flat year-over-year cost per admission in Q2 and targets 4-6% long-term adjusted EBITDA growth. Peers Tenet Healthcare and Universal Health Services are similarly pursuing operational efficiency initiatives.